Decreasing the incidence and impact of infections in neutropenic patients: evidence from meta-analyses of randomized controlled trials

References

• Minneci PC, Deans KJ, Banks SM, et al. Meta-Analysis: The effect of steroids on survival and shock during sepsis depends on the dose. Ann Intern Med 2004;141:47–56
   PubMed Web of Science ®Google Scholar
• Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007;356:2457–71
   PubMed Web of Science ®Google Scholar
• DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Cllin Trials 1986;7:177–88
   PubMedGoogle Scholar
• Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 1959;22:719–48
   PubMed Web of Science ®Google Scholar
• Cochrane Collaboration. Review Manager 4.2 User guide. Acessed on October 30th 2007. http://www.cc-ims.net/download/revman/Documentation/User%20guide.pdf
   Google Scholar
• Egger M, Davey Smith G, Schneider M, et al. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997;315:629–34
   PubMed Web of Science ®Google Scholar
• Sung L, Nathan PC, Lange B, et al. Prophylactic granulocyte colony-stimulating factor and granulocyte-macrophage colonystimulating factor decrease febrile neutropenia after chemotherapy in children with cancer: a meta-analysis of randomized controlled trials. J Clin Oncol 2004;22:3350–6
   PubMed Web of Science ®Google Scholar
• Sasse EC, Sasse AD, Brandalise S, et al. Colony stimulating factors for prevention of myelosupressive therapy induced febrile neutropenia in children with acute lymphoblastic leukaemia. Cochrane Database Syst Rev 2005;CD004139
   Google Scholar
• Lyman GH, Kuderer NM, Djulbegovic B. Prophylactic granulocyte colony-stimulating factor in patients receiving dose-intensive cancer chemotherapy: a meta-analysis. Am J Med 2002;112:406–11
   Google Scholar
• Hackshaw A, Sweetenham J, Knight A. Are prophylactic haematopoietic growth factors of value in the management of patients with aggressive non-Hodgkin’s lymphoma? Br J Cancer 2004;90:1302–5
   Google Scholar
• Dekker A, Bulley S, Beyene J, et al. Meta-analysis of randomized controlled trials of prophylactic granulocyte colony-stimulating factor and granulocyte-macrophage colony stimulating factor after autologous and allogeneic stem cell transplantation. J Clin Oncol 2006;24:5207–15
   PubMed Web of Science ®Google Scholar
• Gafter-Gvili A, Fraser A, Paul M, et al. Meta-analysis: antibiotic prophylaxis reduces mortality in neutropenic patients. Ann Intern Med 2005;142:979–95
   Google Scholar
• van de Wetering MD, de Witte MA, Kremer LC, et al. Efficacy of oral prophylactic antibiotics in neutropenic afebrile oncology patients: a systematic review of randomised controlled trials. Eur J Cancer 2005;41:1372–82
   PubMed Web of Science ®Google Scholar
• Cruciani M, Rampazzo R, Malena M, et al. Prophylaxis with fluoroquinolones for bacterial infections in neutropenic patients: a meta-analysis. Clin Infect Dis 1996;23:795–805
   PubMed Web of Science ®Google Scholar
• Engels EA, Lau J, Barza M. Efficacy of quinolone prophylaxis in neutropenic cancer patients: a meta-analysis. J Clin Oncol 1998;16:1179–87
   PubMed Web of Science ®Google Scholar
• Cruciani M, Malena M, Bosco O, et al. Reappraisal with meta-analysis of the addition of Gram-positive prophylaxis to fluoroquinolone in neutropenic patients. J Clin Oncol 2003;21:4127–37
   PubMed Web of Science ®Google Scholar
• Gotzsche PC, Johansen HK. Meta-analysis of prophylactic or empirical antifungal treatment versus placebo or no treatment in patients with cancer complicated by neutropenia. BMJ 1997;314:1238–44
   PubMed Web of Science ®Google Scholar
• Bow EJ, Laverdière M, Lussier N, et al. Antifungal prophylaxis for severely neutropenic chemotherapy recipients: a meta analysis of randomized-controlled clinical trials. Cancer 2002;94:3230–46
   PubMed Web of Science ®Google Scholar
• Kanda Y, Yamamoto R, Chizuka A, et al. Prophylactic action of oral fluconazole against fungal infection in neutropenic patients. A meta-analysis of 16 randomized, controlled trials. Cancer 2000;89: 1611–25
   Google Scholar
• Glasmacher A, Prentice A, Gorschluter M, et al. Itraconazole prevents invasive fungal infections in neutropenic patients treated for hematologic malignancies: evidence from a meta-analysis of 3,597 patients. J Clin Oncol 2003;21:4615–26
   PubMed Web of Science ®Google Scholar
• Vardakas KZ, Michalopoulos A, Falagas ME. Fluconazole versus itraconazole for antifungal prophylaxis in neutropenic patients with haematological malignancies: a meta-analysis of randomised-controlled trials. Br J Haematol 2005; 131:22–8
   Google Scholar
• Eckmanns T, Ruden H, Gastmeier P. The influence of high efficiency particulate air filtration on mortality and fungal infection among highly immunosuppressed patients: a systematic review. J Infect Dis 2006;193:1408–18
   Google Scholar
• Paul M, Soares-Weiser K, Leibovici L. Beta lactam monotherapy versus beta lactam-aminoglycoside combination therapy for fever with neutropenia: systematic review and meta-analysis. BMJ 2003;326:1111
   PubMed Web of Science ®Google Scholar
• Furno P, Bucaneve G, Del Favero A. Monotherapy or aminoglycoside-containing combinations for empirical antibiotic treatment of febrile neutropenic patients: a meta-analysis. Lancet Infect Dis 2002;2:231–42
   Google Scholar
• Sanders JW, Powe NR, Moore RD. Ceftazidime monotherapy for empiric treatment of febrile neutropenic patients: a meta-analysis. J Infect Dis 1991;164:907–16
   Google Scholar
• Elting LS, Rubenstein EB, Rolston KV, et al. Outcomes of bacteremia in patients with cancer and neutropenia: observations from two decades of epidemiological and clinical trials. Clin Infect Dis 1997;25:247–59
   PubMed Web of Science ®Google Scholar
• Bliziotis IA, Michalopoulos A, Kasiakou SK, et al. Ciprofloxacin versus an aminoglycoside in combination with a beta-lactam for the treatment of febrile neutropenia: a meta-analysis of randomized controlled trials. Mayo Clin Proc 2005;80:1146–56
   PubMed Web of Science ®Google Scholar
• Paul M, Yahav D, Fraser A, et al. Empirical antibiotic monotherapy for febrile neutropenia: systematic review and meta-analysis of randomized controlled trials. J Antimicrob Chemother 2006;57:176–89
   PubMed Web of Science ®Google Scholar
• Furno P, Dionisi MS, Bucaneve G, et al. Ceftriaxone versus beta-lactams with antipseudomonal activity for empirical, combined antibiotic therapy in febrile neutropenia: a meta-analysis. Support Care Cancer 2000;8:293–301
   PubMed Web of Science ®Google Scholar
• Vidal L, Paul M, Ben-Dor I, et al. Oral versus intravenous antibiotic treatment for febrile neutropenia in cancer patients: a systematic review and meta-analysis of randomized trials. J Antimicrob Chemother 2004;54:29–37
   Google Scholar
• Hughes WT, Armstrong D, Bodey GP, et al. 2002 Guidelines for the Use of Antimicrobial Agents in Neutropenic Patients with Cancer. Clin Infect Dis 2002;34:730–51
   Web of Science ®Google Scholar
• Paul M, Borok S, Fraser A, et al. Empirical antibiotics against Gram-positive infections for febrile neutropenia: systematic review and meta-analysis of randomized controlled trials. J Antimicrob Chemother 2005;55:436–44
   PubMed Web of Science ®Google Scholar
• Vardakas KZ, Samonis G, Chrysanthopoulou SA, et al. Role of glycopeptides as part of initial empirical treatment of febrile neutropenic patients: a meta-analysis of randomised controlled trials. Lancet Infect Dis 2005;5:431–9
   PubMed Web of Science ®Google Scholar
• Vancomycin added to empirical combination antibiotic therapy for fever in granulocytopenic cancer patients. European Organization for Research and Treatment of Cancer (EORTC) International Antimicrobial Therapy Cooperative Group and the National Cancer Institute of Canada-Clinical Trials Group. J Infect Dis 1991;163:951–8
   PubMedGoogle Scholar
• Johansen HK, Gotzsche PC. Amphotericin B lipid soluble formulations vs. amphotericin B in cancer patients with neutropenia. Cochrane Database Syst Rev 2005;CD000969
   Google Scholar
• Johansen HK, Gotzsche PC. Amphotericin B versus fluconazole for controlling fungal infections in neutropenic cancer patients. Cochrane Database Syst Rev 2005;CD000239
   Google Scholar
• Jorgensen KJ, Gotzsche PC, Johansen HK. Voriconazole versus amphotericin B in cancer patients with neutropenia. Cochrane Database Syst Rev 2006;CD00472
   Google Scholar
• Wunderink RG, Rello J, Cammarata SK, et al: Linezolid vs vancomycin: analysis of two double-blind studies of patients with methicillin-resistant Staphylococcus aureus nosocomial pneumonia. Chest 2003;124:1789–97
   PubMed Web of Science ®Google Scholar
• Shorr AF, Kunkel MJ, Kollef M: Linezolid versus vancomycin for Staphylococcus aureus bacteraemia: pooled analysis of randomized studies. J Antimicrob Chemother 2005;56:923–9
   PubMed Web of Science ®Google Scholar
• Falagas ME, Siempos II, Vardakas KZ. Linezolid versus a glycopeptide or β-lactam for treatment of Gram-positive bacterial infections: a meta-analysis of randomized controlled trials. Lancet Infect Dis 2008 (in print)
   Google Scholar
• Vardakas KZ, Ntziora F, Falagas ME. Linezolid: effectiveness and safety for approved and off-label indications. Expert Opin Pharmacother 2007;8:2381–400
   Google Scholar
• Jaksic B, Martinelli G, Perez-Oteyza J, et al. Efficacy and safety of linezolid compared with vancomycin in a randomized, double-blind study of febrile neutropenic patients with cancer. Clin Infect Dis 2006;42:597–607
   Google Scholar